<DOC>
	<DOCNO>NCT00118261</DOCNO>
	<brief_summary>RATIONALE : Erlotinib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , oxaliplatin , leucovorin , fluorouracil , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Erlotinib may help chemotherapy work well make tumor cell sensitive drug . Giving erlotinib together combination chemotherapy bevacizumab may kill tumor cell . PURPOSE : This phase I trial study side effect best dose erlotinib give together combination chemotherapy bevacizumab first-line therapy treat patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Erlotinib , Modified FOLFOX6 , Bevacizumab First-Line Therapy Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity erlotinib , mFOLFOX6 , bevacizumab patient metastatic colorectal cancer . - Determine efficacy regimen patient . - Determine feasibility escalate dose erlotinib order maximize likelihood develop grade 2 skin rash select patient . OUTLINE : This multicenter study . - Single-agent erlotinib : Patients receive oral erlotinib daily day 1-14 ( course 1 ) . - Erlotinib , modify FOLFOX6 , bevacizumab chemotherapy : Patients receive oral erlotinib* daily day 1-14 , oxaliplatin IV 2 hour leucovorin calcium IV 2 hour day 1 , fluorouracil IV continuously 46 hour day 1 2 course 2 . Beginning course 3 , patient also receive bevacizumab IV 30 minute . Courses repeat every 14 day absence disease progression unacceptable toxicity . NOTE : Patients develop grade 2 toxicity first 3 course ( 6 week ) erlotinib dose escalate . PROJECTED ACCRUAL : A total 22 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal cancer Biopsyaccessible metastatic disease Measurable disease No CNS metastases PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 3 month Hematopoietic WBC ≥ 4,000/mm^3 OR Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL No bleeding disorder Hepatic Bilirubin ≤ 1.5 mg/dL Albumin ≥ 2.5 g/dL Renal Creatinine ≤ 1.5 mg/dL Urine protein : creatine ratio &lt; 1.0 Cardiovascular Blood pressure ≤ 150/100 mmHg No arterial thrombotic event within past 6 month No New York Heart Association grade IIIV congestive heart failure Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month completion study treatment No malignancy within past 3 year except nonmelanoma skin cancer , carcinoma situ cervix , malignancy &lt; 10 % chance relapse within 3 year No uncontrolled infection No severe uncontrolled illness would preclude study participation No peripheral neuropathy interfere function No abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 6 month No serious nonhealing wound , ulcer , bone fracture PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy No concurrent sargramostim ( GMCSF ) Chemotherapy No prior chemotherapy , include oxaliplatin , metastatic disease Prior adjuvant oxaliplatin allow provided disease progress &gt; 12 month completion oxaliplatin At least 3 week since prior cytotoxic chemotherapy ( 6 week mitomycin nitrosoureas ) No 2 course prior mitomycin No concurrent chemotherapy Endocrine therapy No concurrent anticancer hormonal therapy Radiotherapy At least 2 week since prior radiotherapy No prior radiotherapy &gt; 15 % bone marrow No concurrent radiotherapy Surgery At least 4 week since prior major surgery At least 1 week since prior minor surgery Other Recovered prior therapy No prior epidermal growth factor receptor inhibitor therapy No concurrent antineoplastic antitumor therapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
</DOC>